Free study guide

How the endocannabinoid system works, step by step

Q: What keeps CB1 in check in spinal pain pathways? The SGIP1 protein

Dresslerova D, et al. J Physiol, 2026 (mouse and lab study): SGIP1 is a protein that controls how much CB1 is available to work at a nerve ending. Mice bred without SGIP1 were less sensitive to heat. After an inflammation was triggered, a research cannabinoid called WIN55,212-2 damped signals at spinal pain synapses more strongly in spinal cord slices from mice lacking SGIP1 than from normal mice. Experiments in cultured sensory neurons matched. The authors describe SGIP1 as a brake on CB1 that matters most during inflammation. Mouse and lab work only.

Q: What does CB1 do in immune cells in psoriasis-like skin inflammation?

Choi H, et al. Adv Sci, 2026 (mostly mouse study): CB1 levels were higher in macrophages (a type of immune cell) in psoriasis skin lesions from both people and mice. In mouse models, blocking CB1 with a drug or deleting its gene reduced psoriasis-like skin thickening and inflammation. The proposed chain: CB1 signaling lowers a protein called AUF1, which normally breaks down the instructions for NLRP3, part of an inflammation alarm complex called the inflammasome. Human skin samples were used to measure CB1. The effects were tested only in mice. Note the effect came from blocking CB1, not activating it.

Q: Can a "molecular glue" make cells break down the CB1 receptor?

Kashkush A, et al. NPJ Drug Discov, 2026 (cell-line study): Starting from rimonabant, a compound that binds CB1, researchers built small molecules that tag CB1 for the cell’s protein-disposal system (the proteasome). The most active one, MG-CB2, lowered CB1 levels in breast cancer (MCF-7) and liver cancer (HepG2) cell lines. With less CB1, signaling linked to CB1 dropped, and the cells were less viable and migrated less. Lab cell lines only. The senior author is a founder of Renasis.bio and sits on its scientific advisory board, per the paper’s competing-interests statement.

Q: Can a compound switch on CB1 without using its main binding pocket?

Eldeeb K, et al. Molecules, 2026 (lab and computer-model study): JKH1 and JKH10, two lab compounds related to the antihistamine diphenylpyraline, activated CB1 signaling in mouse nerve-derived cells grown in the lab. Both relaxed isolated mouse arteries, but only JKH10’s effect was blocked by a CB1 blocker. Computer docking suggested they bind at cholesterol or pregnenolone sites on the receptor’s surface rather than the main pocket (the orthosteric site) where anandamide and THC bind. Binding away from the main pocket is called allosteric. Lab and computer-model work only.

Q: What protein does CBD bind in colorectal cancer cells? A lab study

Yu H, et al. J Am Chem Soc, 2026 (cell study): Using a new method for finding which proteins a natural compound binds, the researchers report that CBD latches onto a pair of proteins, CDC123 and eIF2γ, and breaks the pair apart. In colorectal cancer cells grown in the lab, this kept a cell alarm system called the integrated stress response switched on and led to programmed cell death (apoptosis). Cells in dishes only. It can’t show what happens in people.

Q: How does CBD act through PPARγ in melanoma cells? A cell and mouse study

Zhang X, et al. Phytomedicine, 2026 (cell and mouse study): In melanoma cells, CBD slowed growth and invasion and increased apoptosis. In a mouse model, fewer tumors spread to the lungs. The team traced the effect to PPARγ, a receptor inside the cell (not CB1 or CB2). CBD led PPARγ to team up with TET1, an enzyme that removes methyl "off" tags from DNA, which switched on a gene called LRSAM1. Cell and mouse work only. It can’t show what happens in people.

Q: Do CBD or CBG combined with a boron compound act the same in every colon cancer cell line?

Yüksel B, et al. Molecules, 2026 (cell-culture study): Researchers paired sodium pentaborate, a boron compound, with CBD or cannabigerol (CBG) at levels that weren’t toxic to the cells on their own, in two colorectal cancer cell lines. In HT-29 cells, the combinations slowed growth, with synergy only at certain combinations. In HCT-116 cells, they mostly paused the cell cycle and set off stress signaling rather than killing more cells. Cell culture only. The main lesson is that the same combination behaved differently in two cell lines.

Q: How does the endocannabinoid system change as the brain ages?

Zimmer A. Nat Rev Neurosci, 2026 (review article): This review describes endocannabinoid signaling as fairly high in early adulthood and declining with age. In animal studies, disrupting the system impaired processes tied to brain ageing, such as control of brain inflammation, new neuron formation, synaptic plasticity and memory performance. In old animals, THC treatment improved several ageing-related brain traits; the review stresses this is animal research. A review of earlier research, not new experiments. The author writes that clinical evidence in older humans remains limited.

A plain-language tour of the receptors, signaling molecules and enzymes that make up the endocannabinoid system (ECS), plus the plant chemistry that first led scientists to it. Written for curious students. No background needed.

Educational only, not medical advice. This page explains basic biochemistry. It does not recommend any product, dose or use, and it makes no health claims.

1 · The basics 2 · Plant vs body 3 · Terpenes 4 · Plant synergy 5 · Key discoveries 6 · New research 7 · Glossary 8 · Self-check quiz 9 · Reading list

Chapter 1

The basics: CB1 and CB2 receptors, messengers and clean-up enzymes

The endocannabinoid system is a cell-signaling system found throughout the body. Like any signaling system, it has three parts: receptors that receive a signal, messenger molecules that carry it, and enzymes that build the messengers and break them down.

Figure 1. Retrograde signaling. Endocannabinoids (2-AG and anandamide, AEA) are made by the receiving neuron and travel backward to CB1 receptors on the sending neuron, which turns down neurotransmitter release. MAGL and FAAH break the messengers down. (Simplified.)

The two classic receptors

CB1 is one of the most abundant G protein-coupled receptors in the brain. It sits mostly on the sending side of synapses, where it acts like a dimmer switch on neurotransmitter release.

CB2 is found mainly on immune cells and in immune tissues such as the spleen, with smaller amounts elsewhere. It's an active research topic in immunology.

Key idea: Most neurotransmitters travel forward, from the sending cell to the receiving cell. Endocannabinoids usually travel the other way. That's called retrograde signaling, and it gives the receiving cell a way to "talk back."

Built on demand, cleared quickly

Unlike many neurotransmitters, endocannabinoids aren't stored in vesicles. Cells make them from fats in the cell membrane when they're needed, and enzymes break them down soon after. Signals stay short and local.

Figure 2. The two best-studied endocannabinoids follow parallel paths. Anandamide is mainly broken down by FAAH (fatty acid amide hydrolase). 2-AG is mainly broken down by MAGL (monoacylglycerol lipase). Real pathways have more branches than shown here.

Chapter 2

Plant vs body compounds: THC, CBD, anandamide and 2-AG

Endocannabinoids ("endo" = within) are made by the body. Phytocannabinoids ("phyto" = plant) are made by the cannabis plant, which produces more than a hundred of them. Scientists found the plant compounds first, and studying how they act led to the discovery of the body's own system.

Molecule	Made by	What biochemists know
Anandamide (AEA)	The body	A fatty-acid-derived messenger. Its name comes from the Sanskrit word ananda, meaning "bliss." It binds CB1 and, more weakly, CB2. It's broken down by FAAH.
2-AG	The body	A glycerol-based messenger found at much higher levels in the brain than anandamide. It activates both CB1 and CB2. It's broken down mainly by MAGL.
THC (Δ9-tetrahydrocannabinol)	The plant	The best-known phytocannabinoid. It's a partial agonist at CB1 and CB2. Its action at CB1 explains its effects on the brain.
CBD (cannabidiol)	The plant	Binds only weakly to CB1 and CB2 and interacts with several other molecular targets. Exactly how it acts is still being studied.
CBG (cannabigerol)	The plant	Its acid form, CBGA, is the shared starting material the plant uses to build THCA and CBDA.
THCA / CBDA	The plant	The plant mostly makes these "acid" forms. Heat removes a carboxyl group as CO₂ (decarboxylation), turning them into THC and CBD.

Analogy: If CB1 is a lock, anandamide and 2-AG are the body's own keys. Some plant molecules happen to fit the same lock, some fit loosely and some work on different locks entirely.

Chapter 3

Terpenes vs cannabinoids: the aroma chemistry

Terpenes are a huge family of plant molecules built from five-carbon isoprene units. They give many plants their smell. The same terpenes found in cannabis also occur in herbs, fruit and trees.

Myrcene

An earthy, musky monoterpene.

Also in: hops, lemongrass

Limonene

The main scent molecule of citrus peel.

Also in: oranges, lemons

α-Pinene

A sharp, fresh monoterpene that smells like a forest.

Also in: pine needles, rosemary

Linalool

A floral monoterpene alcohol.

Also in: lavender, coriander

β-Caryophyllene

A spicy sesquiterpene (15 carbons). Lab research found it binds CB2 (see Chapter 5).

Also in: black pepper, cloves

Humulene

A woody sesquiterpene closely related to caryophyllene.

Also in: hops

Science in progress: The "entourage effect" is a hypothesis that plant compounds act differently together than alone. It's a popular idea, but the evidence so far is limited and debated. Treat it as an open research question. Chapter 4 walks through the evidence on both sides.

Chapter 4

Plant synergy and the "entourage effect": what the evidence says

A plant never makes just one compound. It makes hundreds at once. That raises a fair science question: does the mixture act differently than each compound alone? Sometimes the answer is a well-measured yes. Sometimes it's still unknown. This chapter shows how scientists tell the difference.

1 + 1 = 2Additive: the combined effect equals the sum of the parts.

1 + 1 > 2Synergy: together they do more than the sum would predict.

1 + 1 < 2Antagonism: one compound weakens or blocks the other.

Figure 3. Two ways compounds can team up. Pharmacokinetic synergy changes how much of a compound gets into the body and how long it stays. Pharmacodynamic synergy changes what compounds do once they reach their targets. (Simplified.)

Pharmacokinetic synergy, in plain words

"What the body does to the compound." One compound changes how well another is absorbed, how fast it's broken down or how quickly it's cleared. The second compound doesn't have to do anything itself. It just helps the first one stick around.

Pharmacodynamic synergy, in plain words

"What the compound does to the body." Two compounds act on the same target, or on different steps of the same pathway, so the combined response is bigger than either one alone.

How synergy is proven: Researchers test each compound alone and then together, over a range of amounts, and compare the result with what simple addition predicts. Without that side-by-side test, "they work better together" is only a hypothesis. (Williamson 2001; Wagner & Ulrich-Merzenich 2009)

Case study: turmeric and black pepper

The problem. Curcumin, the yellow compound in turmeric, is poorly absorbed. The liver and intestinal wall also clear it quickly, largely through a clean-up reaction called glucuronidation. So very little reaches the blood. (Anand et al. 2007)

The partner. Piperine, the compound that makes black pepper taste hot, inhibits glucuronidation in the liver and gut.

The 1998 study. Shoba and colleagues gave curcumin with and without piperine to rats and to healthy human volunteers. In people, curcumin alone gave blood levels that were very low or undetectable. With piperine, the measured bioavailability rose by about 2000% (roughly 20-fold). In rats the increase was 154%. (Shoba et al. 1998)

Follow-up. Reviews of curcumin still list piperine as a classic way to raise bioavailability (Anand et al. 2007; Hewlings & Kalman 2017). The same mechanism isn't limited to curcumin: piperine also raised blood levels of EGCG, a green tea compound, in mice (Lambert et al. 2004).

Read it carefully: This is a pharmacokinetic example. Piperine changes how much curcumin gets into the blood. The study was small, measured blood levels over a few hours and didn't measure any health outcome. Higher blood levels and health benefits aren't the same thing.

One plant, opposite chemistry

Synergy isn't always good news, and a plant isn't "good" or "bad" as a whole. Many plants make some compounds that cause cancer in lab tests and others that are studied for protecting against it. A classic paper made the point that the everyday diet contains natural carcinogens as well as natural anticarcinogens (Ames 1983). A later analysis found that in high-dose rodent tests, roughly half of natural and synthetic chemicals tested came out as carcinogens, so the amount matters a great deal (Ames, Profet & Gold 1990).

Plant	Compound of concern	Compound studied as protective	What scientists report
Coffee	Acrylamide, which forms when plant foods are roasted or cooked at high heat. It's a carcinogen in lab animals (NCI).	Antioxidant compounds	In 2016, the WHO's cancer agency (IARC) reviewed more than 1,000 studies. It rated coffee drinking "not classifiable" (Group 3), found strong evidence of antioxidant effects in people and saw reduced risks for liver and uterine (endometrial) cancers (Loomis et al. 2016).
Broccoli and other crucifers	Indole glucosinolates. They can break down into indole-3-carbinol, which can enhance tumor formation in some studies.	Sulforaphane, which switches on the body's "phase 2" detox enzymes	Broccoli sprout extracts reduced mammary tumors in a rat model. The same paper notes that mature broccoli carries more of the indole compounds (Fahey et al. 1997; Ames et al. 1990).
Bracken fern	Ptaquiloside, a potent carcinogen in lab animals that damages DNA	None well established	Causes bladder tumors in cattle. Studies in Japan and Brazil link eating bracken to upper digestive tract cancers (Alonso-Amelot & Avendaño 2002).
Comfrey	Up to 14 pyrrolizidine alkaloids	None well established	Linked to liver damage in livestock and people, and to cancer in lab animals (Mei et al. 2010).
Sassafras	Safrole, the main compound in sassafras oil	None well established	Caused liver tumors in rodents. U.S. agencies list it as "reasonably anticipated to be a human carcinogen," and the U.S. banned adding it to food in 1960 (NTP).

Key idea: "Natural" doesn't mean safe, and one molecule doesn't define a whole plant. Effects depend on which compounds are present, how much of each and how they interact.

The cannabis "entourage effect": a debated hypothesis

Where the term came from. In 1998, Ben-Shabat, Mechoulam and colleagues coined "entourage effect" for the body's own chemistry, not the plant's. Two fatty acid glycerol esters that don't bind cannabinoid receptors themselves boosted the activity of the endocannabinoid 2-AG in lab and mouse tests (Ben-Shabat et al. 1998).

How it grew. A widely cited 2011 review proposed that plant cannabinoids and terpenes might act in synergy. The author framed it as a possibility, writing that such synergy, "if proven," could open the way to new products (Russo 2011). Since then, the term has spread far beyond the lab.

Evidence that fits the idea

The original 1998 finding: inactive body compounds boosted 2-AG (Ben-Shabat et al. 1998).
In mice, four terpenes (α-humulene, geraniol, linalool and β-pinene) produced cannabinoid-like behaviors and activated CB1 in cell tests. Their effects added to those of a synthetic cannabinoid (LaVigne et al. 2021).

Evidence against it

Six common cannabis terpenes didn't activate CB1 or CB2 or change THC's signaling in human-receptor cell tests (Santiago et al. 2019).
Binding and function tests found no direct terpene effects at CB1 or CB2, alone or mixed with THC, CBD or 2-AG. The one possible exception was a weak β-caryophyllene effect at CB2 (Finlay et al. 2020).
Terpenes also didn't change cannabinoid activity at two TRP ion channels (Heblinski et al. 2020).
A critical review argues the term is ill-defined and widely used in marketing (Cogan 2020).

Where things stand: The cannabis entourage effect is still debated. A 2023 scoping review found the research "in its infancy," with simple methods, conflicting results and clinical claims resting mostly on anecdotes (Christensen et al. 2023). Different labs using different tests have reached opposite conclusions. Treat it as an unproven hypothesis, not an established fact.

References for this chapter

Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine. 2001;8(5):401-9. PubMed 11695885 · doi:10.1078/0944-7113-00060
Wagner H, Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine. 2009;16(2-3):97-110. PubMed 19211237 · doi:10.1016/j.phymed.2008.12.018
Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Medica. 1998;64(4):353-6. PubMed 9619120 · doi:10.1055/s-2006-957450
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Molecular Pharmaceutics. 2007;4(6):807-18. PubMed 17999464 · doi:10.1021/mp700113r
Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92. PubMed 29065496 · doi:10.3390/foods6100092
Lambert JD, Hong J, Kim DH, et al. Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice. Journal of Nutrition. 2004;134(8):1948-52. PubMed 15284381 · doi:10.1093/jn/134.8.1948
Ames BN. Dietary carcinogens and anticarcinogens. Science. 1983;221(4617):1256-64. PubMed 6351251 · doi:10.1126/science.6351251
Ames BN, Profet M, Gold LS. Nature's chemicals and synthetic chemicals: comparative toxicology. PNAS. 1990;87(19):7782-6. PubMed 2217211 · doi:10.1073/pnas.87.19.7782
Loomis D, Guyton KZ, Grosse Y, et al. (IARC Monograph Working Group). Carcinogenicity of drinking coffee, mate, and very hot beverages. Lancet Oncology. 2016;17(7):877-8. PubMed 27318851 · doi:10.1016/S1470-2045(16)30239-X · IARC Monograph 116 (NCBI Bookshelf)
National Cancer Institute. Acrylamide and Cancer Risk (fact sheet). cancer.gov
Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. PNAS. 1997;94(19):10367-72. PubMed 9294217 · doi:10.1073/pnas.94.19.10367
Alonso-Amelot ME, Avendaño M. Human carcinogenesis and bracken fern: a review of the evidence. Current Medicinal Chemistry. 2002;9(6):675-86. PubMed 11945131 · doi:10.2174/0929867023370743
Mei N, Guo L, Fu PP, et al. Metabolism, genotoxicity, and carcinogenicity of comfrey. J Toxicol Environ Health B Crit Rev. 2010;13(7-8):509-26. PubMed 21170807 · doi:10.1080/10937404.2010.509013
National Toxicology Program. Report on Carcinogens, 15th ed.: Safrole. ntp.niehs.nih.gov
Ben-Shabat S, Fride E, Sheskin T, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology. 1998;353(1):23-31. PubMed 9721036 · doi:10.1016/s0014-2999(98)00392-6
Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011;163(7):1344-64. PubMed 21749363 · doi:10.1111/j.1476-5381.2011.01238.x
Santiago M, Sachdev S, Arnold JC, et al. Absence of entourage: terpenoids commonly found in Cannabis sativa do not modulate the functional activity of Δ9-THC at human CB1 and CB2 receptors. Cannabis and Cannabinoid Research. 2019;4(3):165-76. PubMed 31559333 · doi:10.1089/can.2019.0016
Finlay DB, Sircombe KJ, Nimick M, et al. Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors. Frontiers in Pharmacology. 2020;11:359. PubMed 32269529 · doi:10.3389/fphar.2020.00359
Heblinski M, Santiago M, Fletcher C, et al. Terpenoids commonly found in Cannabis sativa do not modulate the actions of phytocannabinoids or endocannabinoids on TRPA1 and TRPV1 channels. Cannabis and Cannabinoid Research. 2020;5(4):305-17. PubMed 33376801 · doi:10.1089/can.2019.0099
LaVigne JE, Hecksel R, Keresztes A, Streicher JM. Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity. Scientific Reports. 2021;11(1):8232. PubMed 33859287 · doi:10.1038/s41598-021-87740-8
Cogan PS. The 'entourage effect' or 'hodge-podge hashish': the questionable rebranding, marketing, and expectations of cannabis polypharmacy. Expert Review of Clinical Pharmacology. 2020;13(8):835-45. PubMed 32116073 · doi:10.1080/17512433.2020.1721281
Christensen C, Rose M, Cornett C, Allesø M. Decoding the postulated entourage effect of medicinal cannabis: what it is and what it isn't. Biomedicines. 2023;11(8):2323. PubMed 37626819 · doi:10.3390/biomedicines11082323

Educational only, not medical advice. This chapter describes published laboratory and population research. It doesn't recommend any plant, product, combination, dose or use, and it makes no health claims.

Chapter 5

Key discoveries

Each milestone links to the original paper's PubMed record.

1990: The CB1 receptor is cloned. Matsuda and colleagues reported the structure of a cannabinoid receptor in Nature. PubMed 2165569
1992: Anandamide is identified. Devane and colleagues isolated a brain molecule that binds the cannabinoid receptor (Science). PubMed 1470919
1993: The CB2 receptor is described. Munro and colleagues characterized a "peripheral" cannabinoid receptor (Nature). PubMed 7689702
1995: 2-AG is identified. Two groups reported 2-arachidonoylglycerol as a second endocannabinoid: Mechoulam and colleagues (PubMed 7605349) and Sugiura and colleagues (PubMed 7575630).
1998: The term "entourage effect" is coined. Ben-Shabat, Mechoulam and colleagues reported that inactive fatty acid glycerol esters made by the body boosted the activity of 2-AG (European Journal of Pharmacology). PubMed 9721036
2008: A dietary terpene binds CB2. Gertsch and colleagues reported that β-caryophyllene binds CB2 (PNAS). PubMed 18574142

Chapter 6

New research, October 2026: receptors, mechanisms and lab studies

Recent papers on how cannabinoid receptors and plant compounds work, summarized from their PubMed abstracts and NIH records. Each summary has its own link you can share, plus the original paper.

Science in progress: Everything in this chapter is lab, animal or review work, or a study that hasn’t reported yet. Results in cells and mice can’t show what happens in people. Cancer cell studies here describe biology in a dish, not treatments.

CB1 receptor research

Mouse and lab study

What keeps CB1 in check in spinal pain pathways? The SGIP1 protein

SGIP1 is a protein that controls how much CB1 is available to work at a nerve ending. Mice bred without SGIP1 were less sensitive to heat. After an inflammation was triggered, a research cannabinoid called WIN55,212-2 damped signals at spinal pain synapses more strongly in spinal cord slices from mice lacking SGIP1 than from normal mice. Experiments in cultured sensory neurons matched. The authors describe SGIP1 as a brake on CB1 that matters most during inflammation.

Keep in mind: Mouse and lab work only.

Dresslerova D, et al. J Physiol. 2026. PubMed 42936972 · doi:10.1113/JP291830

Search terms: SGIP1 · CB1 receptor · spinal cord · pain signaling · inflammation

Link to this summary

Mostly mouse study

What does CB1 do in immune cells in psoriasis-like skin inflammation?

CB1 levels were higher in macrophages (a type of immune cell) in psoriasis skin lesions from both people and mice. In mouse models, blocking CB1 with a drug or deleting its gene reduced psoriasis-like skin thickening and inflammation. The proposed chain: CB1 signaling lowers a protein called AUF1, which normally breaks down the instructions for NLRP3, part of an inflammation alarm complex called the inflammasome.

Keep in mind: Human skin samples were used to measure CB1. The effects were tested only in mice. Note the effect came from blocking CB1, not activating it.

Choi H, et al. Adv Sci. 2026. PubMed 42875876 · doi:10.1002/advs.78313

Search terms: CB1 receptor · macrophages · psoriasis · NLRP3 inflammasome · AUF1

Link to this summary

Cell-line study

Can a "molecular glue" make cells break down the CB1 receptor?

Starting from rimonabant, a compound that binds CB1, researchers built small molecules that tag CB1 for the cell’s protein-disposal system (the proteasome). The most active one, MG-CB2, lowered CB1 levels in breast cancer (MCF-7) and liver cancer (HepG2) cell lines. With less CB1, signaling linked to CB1 dropped, and the cells were less viable and migrated less.

Keep in mind: Lab cell lines only. The senior author is a founder of Renasis.bio and sits on its scientific advisory board, per the paper’s competing-interests statement.

Kashkush A, et al. NPJ Drug Discov. 2026. PubMed 42934270 · doi:10.1038/s44386-026-00087-w

Search terms: CB1 receptor · molecular glue · protein degradation · rimonabant · GPCR

Link to this summary

Lab and computer-model study

Can a compound switch on CB1 without using its main binding pocket?

JKH1 and JKH10, two lab compounds related to the antihistamine diphenylpyraline, activated CB1 signaling in mouse nerve-derived cells grown in the lab. Both relaxed isolated mouse arteries, but only JKH10’s effect was blocked by a CB1 blocker. Computer docking suggested they bind at cholesterol or pregnenolone sites on the receptor’s surface rather than the main pocket (the orthosteric site) where anandamide and THC bind. Binding away from the main pocket is called allosteric.

Keep in mind: Lab and computer-model work only.

Eldeeb K, et al. Molecules. 2026. PubMed 42943769 · doi:10.3390/molecules31203699

Search terms: CB1 receptor · allosteric agonist · diphenylpyraline · orthosteric site · receptor binding

Link to this summary

CBD and CBG in lab studies

Cell study

What protein does CBD bind in colorectal cancer cells? A lab study

Using a new method for finding which proteins a natural compound binds, the researchers report that CBD latches onto a pair of proteins, CDC123 and eIF2γ, and breaks the pair apart. In colorectal cancer cells grown in the lab, this kept a cell alarm system called the integrated stress response switched on and led to programmed cell death (apoptosis).

Keep in mind: Cells in dishes only. It can’t show what happens in people.

Yu H, et al. J Am Chem Soc. 2026. PubMed 41518300 · doi:10.1021/jacs.5c20040

Search terms: cannabidiol · CDC123 · eIF2γ · colorectal cancer cells · integrated stress response

Link to this summary

Cell and mouse study

How does CBD act through PPARγ in melanoma cells? A cell and mouse study

In melanoma cells, CBD slowed growth and invasion and increased apoptosis. In a mouse model, fewer tumors spread to the lungs. The team traced the effect to PPARγ, a receptor inside the cell (not CB1 or CB2). CBD led PPARγ to team up with TET1, an enzyme that removes methyl "off" tags from DNA, which switched on a gene called LRSAM1.

Keep in mind: Cell and mouse work only. It can’t show what happens in people.

Zhang X, et al. Phytomedicine. 2026. PubMed 41547069 · doi:10.1016/j.phymed.2026.157775

Search terms: cannabidiol · PPARγ · TET1 · DNA methylation · melanoma cells

Link to this summary

Cell-culture study

Do CBD or CBG combined with a boron compound act the same in every colon cancer cell line?

Researchers paired sodium pentaborate, a boron compound, with CBD or cannabigerol (CBG) at levels that weren’t toxic to the cells on their own, in two colorectal cancer cell lines. In HT-29 cells, the combinations slowed growth, with synergy only at certain combinations. In HCT-116 cells, they mostly paused the cell cycle and set off stress signaling rather than killing more cells.

Keep in mind: Cell culture only. The main lesson is that the same combination behaved differently in two cell lines.

Yüksel B, et al. Molecules. 2026. PubMed 42796493 · doi:10.3390/molecules31183206

Search terms: cannabigerol (CBG) · cannabidiol · sodium pentaborate · boron · colorectal cancer cells

Link to this summary

Big-picture review

Review article

How does the endocannabinoid system change as the brain ages?

This review describes endocannabinoid signaling as fairly high in early adulthood and declining with age. In animal studies, disrupting the system impaired processes tied to brain ageing, such as control of brain inflammation, new neuron formation, synaptic plasticity and memory performance. In old animals, THC treatment improved several ageing-related brain traits; the review stresses this is animal research.

Keep in mind: A review of earlier research, not new experiments. The author writes that clinical evidence in older humans remains limited.

Zimmer A. Nat Rev Neurosci. 2026. PubMed 42888282 · doi:10.1038/s41583-026-01085-7

Search terms: endocannabinoid system · brain ageing · neuroinflammation · synaptic plasticity · review

Link to this summary

NIH-funded study underway

Funded study underway

How does CBD reshape synapses in the developing brain? An NIH-funded mouse study

A two-year exploratory grant, awarded in September 2026, to study the developing prefrontal cortex of normal mice. Researchers will test whether CBD strengthens inhibitory (calming) synapses and, in turn, leads to pruning of excitatory synapses, shifting the excitatory/inhibitory balance. The project is meant to lay groundwork for later studies in mouse models of Dravet syndrome.

Keep in mind: Funded through August 2028. Mouse work. No results published yet.

University of Colorado Denver. Funded by the National Institute of Neurological Disorders and Stroke (NINDS). NIH RePORTER 11513736

Search terms: cannabidiol · synapses · excitatory/inhibitory balance · prefrontal cortex · NIH-funded study

Link to this summary

Educational only, not medical advice. This chapter describes laboratory, animal and review research. It doesn’t recommend any product, dose or use, and it makes no health claims.

Chapter 7

Endocannabinoid system glossary

Quick definitions for the terms used on this page.

Agonist: A molecule that binds a receptor and activates it. A partial agonist activates it only partway.
Antagonist: A molecule that binds a receptor and blocks it without activating it.
CB1 / CB2: The two classic cannabinoid receptors. CB1 is mostly in the nervous system and CB2 mostly in immune cells.
G protein-coupled receptor (GPCR): A large family of membrane receptors that pass signals into the cell through G proteins. CB1 and CB2 are GPCRs.
Endocannabinoid: A cannabinoid made by the body, such as anandamide or 2-AG.
Phytocannabinoid: A cannabinoid made by a plant, such as THC or CBD.
FAAH: Fatty acid amide hydrolase, the main enzyme that breaks down anandamide.
MAGL: Monoacylglycerol lipase, the main enzyme that breaks down 2-AG.
Retrograde signaling: Signaling that travels from the receiving neuron back to the sending neuron.
Synapse: The junction where one neuron passes a signal to another.
Decarboxylation: A reaction that removes a carboxyl group and releases CO₂, as when THCA becomes THC.
Terpene: A plant molecule built from five-carbon isoprene units. Monoterpenes have 10 carbons and sesquiterpenes have 15.
Bioavailability: The share of a compound that reaches the bloodstream in active form after it is taken in.
Synergy: When two or more compounds together produce a bigger effect than you would predict by adding their separate effects.
Glucuronidation: A clean-up reaction in the liver and gut wall that attaches a sugar acid (glucuronic acid) to a molecule so the body can excrete it.
Entourage effect: A term coined in 1998 for inactive body compounds boosting 2-AG. Today it usually means the debated idea that cannabis compounds act differently together than alone.
Ligand: Any molecule that binds a receptor, whether it activates it or not.
Homeostasis: The body's process of keeping internal conditions stable. The ECS is studied as one of many systems involved.

Chapter 8

Endocannabinoid system self-check quiz

Eight quick questions. Everything runs in your browser. Nothing is saved or sent anywhere.

Chapter 9

Textbooks & reading list

Real books, linked to publisher, library or free-to-read pages. No affiliate links. Start with the free ones.

Free online · Neuroscience background

How the endocannabinoid system works, step by step

The basics: CB1 and CB2 receptors, messengers and clean-up enzymes

The two classic receptors

Built on demand, cleared quickly

Plant vs body compounds: THC, CBD, anandamide and 2-AG

Terpenes vs cannabinoids: the aroma chemistry

Myrcene

Limonene

α-Pinene

Linalool

β-Caryophyllene

Humulene

Plant synergy and the "entourage effect": what the evidence says

Pharmacokinetic synergy, in plain words

Pharmacodynamic synergy, in plain words

Case study: turmeric and black pepper

One plant, opposite chemistry

The cannabis "entourage effect": a debated hypothesis

Evidence that fits the idea

Evidence against it

References for this chapter

Key discoveries

New research, October 2026: receptors, mechanisms and lab studies

CB1 receptor research

What keeps CB1 in check in spinal pain pathways? The SGIP1 protein

What does CB1 do in immune cells in psoriasis-like skin inflammation?

Can a "molecular glue" make cells break down the CB1 receptor?

Can a compound switch on CB1 without using its main binding pocket?

CBD and CBG in lab studies

What protein does CBD bind in colorectal cancer cells? A lab study

How does CBD act through PPARγ in melanoma cells? A cell and mouse study

Do CBD or CBG combined with a boron compound act the same in every colon cancer cell line?

Big-picture review

How does the endocannabinoid system change as the brain ages?

NIH-funded study underway

How does CBD reshape synapses in the developing brain? An NIH-funded mouse study

Endocannabinoid system glossary

Endocannabinoid system self-check quiz

Textbooks & reading list

Neuroscience, 2nd edition

The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research

Marijuana and Medicine: Assessing the Science Base

Lehninger Principles of Biochemistry

Basic Neurochemistry: Principles of Molecular, Cellular, and Medical Neurobiology (8th ed.)

Handbook of Cannabis

Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential